LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
  • Stock Info
  • Disclosure
  • Financial Information
  • IR Inquiries

Disclosure

2025-07-07 20:10:49
No.DateDisclosure Contents
102025.06.11[Investment Caution]small number of accounts being focused on
92025.06.09Organization of Investor Relations Event
82025.03.28Outcomes of Annual Meeting of Shareholders
72025.03.20Submission of Audit Report
62025.03.17Organization of Investor Relations Event
52025.03.12Decision on Paid-in Capital Increase(Material Management Matters of Subsidiary Company)
42025.03.12Reporting reasons for holding general shareholders' meeting on the most concentrated date
32025.03.12Resolutions for Convocation of General Meeting of Shareholders
22025.03.06Organization of Investor Relations Event
12025.02.1930% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)
  • Stock Info
  • Disclosure
  • Financial Information
  • IR Inquiries

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST